Adverse events460

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 460

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	Pegcetacoplan Double Blind During Part A	3	16
other	Fatigue	General disorders	Placebo Matching Pegcetacoplan-Double-blind During Part A	0	8
other	Fatigue	General disorders	Open-label Pegcetacoplan During Parts B and C	0	14
other	Fatigue	General disorders	Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C	0	7
other	Oedema peripheral	General disorders	Pegcetacoplan Double Blind During Part A	3	16
other	Oedema peripheral	General disorders	Placebo Matching Pegcetacoplan-Double-blind During Part A	3	8
other	Oedema peripheral	General disorders	Open-label Pegcetacoplan During Parts B and C	0	14
other	Oedema peripheral	General disorders	Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C	0	7
other	Gait disturbance	General disorders	Pegcetacoplan Double Blind During Part A	0	16
other	Gait disturbance	General disorders	Placebo Matching Pegcetacoplan-Double-blind During Part A	0	8
other	Gait disturbance	General disorders	Open-label Pegcetacoplan During Parts B and C	0	14
other	Gait disturbance	General disorders	Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C	1	7
other	Covid-19	Infections and infestations	Pegcetacoplan Double Blind During Part A	3	16
other	Covid-19	Infections and infestations	Placebo Matching Pegcetacoplan-Double-blind During Part A	1	8
other	Covid-19	Infections and infestations	Open-label Pegcetacoplan During Parts B and C	3	14
other	Covid-19	Infections and infestations	Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C	0	7
other	Upper respiratory tract infection	Infections and infestations	Pegcetacoplan Double Blind During Part A	3	16
other	Upper respiratory tract infection	Infections and infestations	Placebo Matching Pegcetacoplan-Double-blind During Part A	0	8
other	Upper respiratory tract infection	Infections and infestations	Open-label Pegcetacoplan During Parts B and C	1	14
other	Upper respiratory tract infection	Infections and infestations	Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C	0	7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05096403/events

API reference For AI assistants

Adverse events460

Sources 3

Read this list from software.